Payment overview · 2025
General Payments
$2,608.31
127 reported records · 36 companies
Healthcare provider profile · identity verified
Abigail Beth Byrnes, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · CORBIN, KY · NPI 1902902372
Verified facts
What the public records show
CMS Open Payments records show Abigail Beth Byrnes, M.D. received $2,608.31 in general payments during 2025 across 127 reported records.
Merck Sharp & Dohme LLC accounted for 9.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 66 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Imbruvica, Jakafi, Verzenio.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Imbruvica by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Calquence by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jakafi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Imbruvica by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERZENIO as an associated drug or biological on 9278 records involving 4763 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Verzenio by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $237.04 | 9.1% | 11 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $200.91 | 7.7% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $200.19 | 7.7% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $181.38 | 7.0% | 8 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $171.30 | 6.6% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $163.65 | 6.3% | 9 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $154.97 | 5.9% | 4 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $139.45 | 5.3% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $126.29 | 4.8% | 6 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $107.30 | 4.1% | 4 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $72.89 | 2.8% | 3 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $71.54 | 2.7% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $66.76 | 2.6% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $65.48 | 2.5% | 3 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $58.49 | 2.2% | 3 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $53.58 | 2.0% | 3 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.13 | 1.8% | 3 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $41.94 | 1.6% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $40.86 | 1.6% | 2 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $37.19 | 1.4% | 1 | 2025 |
| Cumberland Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.28 | 1.4% | 2 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $35.50 | 1.4% | 2 | 2025 |
| Coherus Oncology, Inc. | Unresolved — no canonical attribution shown | $34.73 | 1.3% | 2 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $32.66 | 1.2% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $31.00 | 1.2% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $23.22 | 0.9% | 1 | 2025 |
| PROGENICS PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $20.70 | 0.8% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.42 | 0.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.00 | 0.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.02 | 0.7% | 1 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $18.20 | 0.7% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $17.72 | 0.7% | 1 | 2025 |
| Iovance Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $16.86 | 0.7% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $15.89 | 0.6% | 1 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $14.05 | 0.5% | 1 | 2025 |
| TerSera Therapeutics LLC | Unresolved — no canonical attribution shown | $13.72 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,398.83 | 123 |
| Education | $209.48 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $237.04 | 11 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $154.97 | 4 | 2025 |
Source payment records
|
|||||
| DARZALEX Normalized: darzalex |
Biological | Janssen Biotech, Inc. | $129.62 | 3 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $129.62 | 3 | 2025 |
Source payment records
|
|||||
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $115.29 | 4 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $114.28 | 6 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | Astellas Pharma US Inc, PFIZER INC. | $113.89 | 7 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $111.29 | 7 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $107.30 | 4 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological, Drug | Astellas Pharma US Inc, PFIZER INC. | $98.84 | 5 | 2025 |
Source payment records
|
|||||
| TECVAYLI Normalized: tecvayli |
Biological | Janssen Biotech, Inc. | $97.48 | 2 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC., Genmab U.S., Inc. | $75.06 | 4 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $66.76 | 4 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $65.48 | 3 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $61.43 | 4 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $60.06 | 3 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $58.49 | 3 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $56.66 | 3 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $55.66 | 4 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $53.58 | 3 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $47.13 | 3 | 2025 |
Source payment records
|
|||||
| Stivarga Normalized: stivarga |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $47.04 | 3 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $46.07 | 2 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $41.94 | 2 | 2025 |
Source payment records
|
|||||
| ADCETRIS Normalized: adcetris |
Biological | PFIZER INC. | $41.67 | 2 | 2025 |
Source payment records
|
|||||
| ELREXFIO Normalized: elrexfio |
Drug | PFIZER INC. | $41.67 | 2 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $41.33 | 2 | 2025 |
Source payment records
|
|||||
| POTELIGEO Normalized: poteligeo |
Drug | KYOWA KIRIN, INC. | $40.86 | 2 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $39.78 | 2 | 2025 |
Source payment records
|
|||||
| Tivdak Normalized: tivdak |
Drug | Genmab U.S., Inc. | $38.41 | 2 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.57 | 2 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $37.19 | 1 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Merck Sharp & Dohme LLC | $36.96 | 2 | 2025 |
Source payment records
|
|||||
| SANCUSO Normalized: sancuso |
Drug | Cumberland Pharmaceuticals, Inc. | $36.28 | 2 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $35.50 | 2 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $35.50 | 2 | 2025 |
Source payment records
|
|||||
| LOQTORZI Normalized: loqtorzi |
Biological | Coherus Oncology, Inc. | $34.73 | 2 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $32.66 | 2 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $28.67 | 2 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $28.41 | 1 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $26.82 | 1 | 2025 |
Source payment records
|
|||||
| ZYNYZ Normalized: zynyz |
Drug | Incyte Corporation | $26.82 | 1 | 2025 |
Source payment records
|
|||||
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $24.90 | 1 | 2025 |
Source payment records
|
|||||
| WELIREG Normalized: welireg |
Drug | Merck Sharp & Dohme LLC | $24.87 | 2 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| LUTATHERA Normalized: lutathera |
Drug | Novartis Pharmaceuticals Corporation | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| PYLARIFY Normalized: pylarify |
Drug | PROGENICS PHARMACEUTICALS, INC. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| BOSULIF Normalized: bosulif |
Drug | PFIZER INC. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| Amtagvi Normalized: amtagvi |
Drug | Iovance Biotherapeutics, Inc. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| INLYTA Normalized: inlyta |
Drug | PFIZER INC. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $14.05 | 1 | 2025 |
Source payment records
|
|||||
| Zoladex Normalized: zoladex |
Drug | TerSera Therapeutics LLC | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| IMBRUVICA imbruvica |
2025 | Imbruvica | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERZENIO verzenio |
2025 | Verzenio | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | VERZENIO open payments reported associated product |
CMS Open Payments — General Payments 9278 supporting records · 4763 recipient NPIs · example record 1186464449 |
Verzenio · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 200 | 56 |
| Ondansetron Hcl | Ondansetron Hcl | 110 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 105 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 88 | 35 |
| Gabapentin | Gabapentin | 75 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 23 |
| Morphine Sulfate Er | Morphine Sulfate | 71 | 16 |
| Letrozole | Letrozole | 62 | 12 |
| Prednisone | Prednisone | 58 | 20 |
| Tamoxifen Citrate | Tamoxifen Citrate | 56 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | 25 |
| Eliquis | Apixaban | 46 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | 22 |
| Lorazepam | Lorazepam | 43 | 19 |
| Olanzapine | Olanzapine | 42 | 15 |
| Abiraterone Acetate | Abiraterone Acetate | 38 | suppressed |
| Dexamethasone | Dexamethasone | 36 | 13 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 31 | 14 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 29 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Xtampza Er | Oxycodone Myristate | 23 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 20 |
| Lactulose | Lactulose | 21 | 12 |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 12 |
| Dronabinol | Dronabinol | 18 | 13 |
| Potassium Chloride | Potassium Chloride | 18 | 15 |
| Nystatin | Nystatin | 17 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Hydroxyurea | Hydroxyurea | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Imbruvica | Ibrutinib | 13 | suppressed |
| Calquence | Acalabrutinib Maleate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 12 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Verzenio | Abemaciclib | 12 | suppressed |
| Votrient | Pazopanib Hcl | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,608.31 · 127 records | Merck Sharp & Dohme LLC | ADCETRIS, Amtagvi, BOSULIF, BRAFTOVI, CARVYKTI, DARZALEX, DATROWAY, ELAHERE, ELREXFIO, ENHERTU, EPKINLY, FOTIVDA, FRUZAQLA, IBRANCE, IMBRUVICA, INLYTA, INQOVI, JAKAFI, JAYPIRCA, KEYTRUDA, KEYTRUDA QLEX, KISQALI, LIBTAYO, LONSURF, LOQTORZI, LUTATHERA, LYNPARZA, MEKTOVI, MI CANCER SEEK, MONJUVI, MONOFERRIC, NERLYNX, Nubeqa, OJJAARA, OPDIVO, ORGOVYX, Onivyde, Orserdu, PADCEV, PLUVICTO, POTELIGEO, PYLARIFY, PYRUKYND, Polivy, RYBREVANT, SANCUSO, SARCLISA, Stivarga, TAGRISSO, TALVEY, TALZENNA, TECVAYLI, TEVIMBRA, Tecentriq, Tivdak, Trodelvy, VENCLEXTA, VERZENIO, Vitrakvi, Vyloy, WELIREG, XPOVIO, XTANDI, Xofigo, ZYNYZ, Zoladex | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Imbruvica play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error